CrossAssetDataThe Company File
···
EYPT

EyePoint, Inc.

EyePoint, Inc. is classed by the SEC under Laboratory Analytical Instruments (industry code 3826), based in Watertown, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $31 million and a loss of $232 million (its filed statements).

Product business Laboratory Analytical Instruments Watertown, MA filings since 2005 8 of 9 filed, 1 estimated
Ask the desk about EYPT → Compare EYPT with QTRX → Price chart on TradingView ↗ Full EDGAR file ↗ Watch EYPT →

Sector peers: QTRXSEERCTKBLAB

3.8/10headline grade
vs its business-model standard
3.3/10past 3.4/10present 4.7/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3826, Laboratory Analytical Instruments); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 3.8 out of ten, 8 of 9 metrics filed and 1 estimated: past 3.3 out of ten, present 3.4 out of ten, future 4.7 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 4.6 out of ten. 2 warning events since 2017; the latest 2021-05-03. 46th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 3.5 out of ten. +18.3% a year over 10 filed years; profitable in 0 of 10. 35th percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 1.2 out of ten. CrossAssetData estimate 1.2/10, confidence 35 of 100 (one part). 12th percentile among 21 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
  • Financial health (present): 4.1 out of ten. ROE -76%: lost 76¢ per shareholder dollar. Leverage 16%: owes 16¢ per asset dollar. 41st percentile among 22 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 1.2 out of ten. bottom 12% of 21 in its family; net margin -739.4%. 12th percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 5.5 out of ten. top 45% of 21 in its family for leadership; chief executive since 2023. 55th percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 6.3 out of ten. top 37% of 21 in its family for room to expand. 63rd percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 5.1 out of ten. top 49% of 21 in its family for growth drivers. 51st percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 0.8 out of ten. bottom 8% of 20 in its family for expectations against reality. 8th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-03-05 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-05 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-05 (on EDGAR). Newest filing: Form SCHEDULE 13G/A, 2026-10-07. Filings on record since 2005. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: License and Collaboration Agreement 53%, Royalty 42%, Product 5%. By geography: United States 96%, China 4%, United Kingdom under 1%. As tagged in its annual report (Form 10-K, filed 2026-03-05).

Who runs it

Duker, Jay S. (President and CEO); Lurker, Nancy (Executive Vice Chair); Elston, George (Chief Financial Officer); Ribeiro, Ramiro (Chief Medical Officer); Zaderej, Karen L. (director); Ando, Goran (director); Dicicco, Wendy F (director); Duty, Stuart (director); Hassan, Fred (director); Landis, John B. (director); and 1 more. 11 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.